Related Experiment Video

Updated: Dec 19, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.0K

RDM1 plays an oncogenic role in human ovarian carcinoma cells

Lu Tong1,2, Wenjiao Cao1, Jun Sheng3

  • 1International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, The China Welfare Institute, Shanghai, China.

Artificial Cells, Nanomedicine, and Biotechnology
|June 6, 2020
PubMed

Insights

RAD52 motif-containing protein 1 (RDM1) promotes ovarian cancer growth and may be a new therapeutic target. Silencing RDM1 inhibits tumor progression and enhances apoptosis in ovarian cancer models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian cancer has a low 5-year survival rate, necessitating new therapeutic strategies.
  • RAD52 motif-containing protein 1 (RDM1) is involved in DNA damage repair and its role in ovarian cancer is unknown.
  • RDM1 is sensitive to cisplatin, a common chemotherapy agent.

Purpose of the Study:

  • To investigate the role of RDM1 in the development and progression of ovarian cancer.
  • To explore RDM1 as a potential therapeutic target for ovarian carcinoma.

Main Methods:

  • Analysis of RDM1 mRNA and protein expression in clinical ovarian carcinoma tissues.
  • In vitro studies involving RDM1 knockdown in ovarian carcinoma cell lines to assess proliferation and apoptosis.
  • In vivo studies using a xenograft mouse model to evaluate the effect of RDM1 knockdown on tumor growth.

Main Results:

  • RDM1 expression is upregulated in ovarian carcinoma tissues.
  • RDM1 knockdown reduces ovarian carcinoma cell proliferation and induces apoptosis in vitro.
  • Stable knockdown of RDM1 significantly inhibits ovarian cancer tumor growth in vivo.
  • RDM1 regulates the p53/RAD51/RAD52 signaling pathway, potentially by negatively regulating p53.

Conclusions:

  • RDM1 plays an oncogenic role in human ovarian carcinoma.
  • RDM1 may serve as a novel therapeutic target for ovarian cancer treatment.
  • RDM1's oncogenic function may be mediated through the regulation of the p53/RAD51/RAD52 pathway.
Keywords:
DNA damage repairOvarian cancerRDM1p53

More Related Videos

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

7.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.0K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.9K